

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: D. Carcanague <i>et al.</i>)	Confirmation No.: 4626
)	
Application No. 10/536,686)	Art Unit: 1625
)	
Filed: May 27, 2005)	Examiner: Patricia L. Morris
)	
For: Oxazolidinone and/or isoxazoline derivatives as antibacterial agents)	Date: February 15, 2008

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. 1.56 and 1.97(b), Applicants request that the Examiner consider this Supplemental Information Disclosure Statement and the document listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced Application. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

The present application is a U.S. National Phase Application of International Application No. PCT/GB03/05087, filed November 24, 2003. The attached document was cited in International Search Report which issued in International Patent Application PCT/GB03/05087. A copy of the International Search Report was submitted on May 27, 2005, and is therefore not attached.

Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Except for issue fees payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

Date: February 15, 2008
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000

By:


Sally P. Teng
Registration No. 45,397
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001